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F
inancial  conflicts  of  interest  (fcoi)  are  of 
particular concern in the conduct of human sub-
ject research, whether they occur at the level of 
individual investigators or at the level of the institution.1 
Institutional  fCOI  can  occur  when  an  institution  that 
hosts the research, or a senior institutional official act-
ing on behalf of the institution, has a financial interest in 
the study outcome.2,3 Such conflicts can be detrimental 
to  research  subjects,4  lead  to  an  inappropriate  degree 
of control over what should be an independent research 
agenda,5 and have serious implications, even in the ab-
sence of research misconducts.6,7 Moreover, undisclosed 
fCOI undermine the public’s confidence in science. 
For  example,  senior  National  Institutes  of  Health 
(NIH) officials were allowed to receive income as consult-
ants to drug companies.6 The concern that this income 
might  inappropriately  influence  their  work  resulted  in 
the formation of a national Blue Ribbon committee to 
examine NIH conflict-of-interest policies.7 The commit-
tee’s 2004 report recommended that senior management 
should not consult with companies whose interests could 
influence the outcomes of their research6 ultimately led to 
a moratorium on industry-paid consultancies held by any 
NIH employee. Despite increased scrutiny of this issue 
on the part of government,6 the media,8 and the public,9 
academic institutions have been slow to develop policies 
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fax: 416-351-3746; paula.rochon@utoronto.ca           related to institutional fCOI.1 We conducted a content an-
alysis of the institutional fCOI policies in use at Canadian 
academic health science centres (AHSCs) to identify gaps 
in policy coverage and to guide policy improvement. 
Our  research  methods  are  more  fully  described  in 
Box 1. In brief, we collected institution-level fCOI poli-
cies from all 16 AHSCs (16 medical schools and 47 teach-
ing  hospitals  as  well  as  their  16  partner  universities) 
from August 2005 to February 2006. These centres are 
the major sites of academic research involving humans 
in Canada. We contacted the vice president (VP) of re-
search (or equivalent) at each site and asked him or her 
to identify 3 key institutional fCOI policies at their insti-
tution. To evaluate policy comprehensiveness, we com-
pared each unique policy to our “standard” of 16 core 
items relevant to institutional fCOI derived from the key 
COI documents.2,10,11
All  16  universities  (100%),  their  16  medical  schools 
(100%), and 42 (89%) of the teaching hospitals responded 
to  our  request  for  policies.  Nine  (56%)  universities,  9 
(56%) medical schools, and 15 (36%) teaching hospitals 
responded that they had no policies on institutional fCOI. 
Of the 72 policies identified, 34 were shared within 
AHSCs. Approximately a quarter (26%) of universities, 
medical schools, and teaching hospitals identified more 
than one institutional fCOI policy. Only 6 (16%) included 
“institutional conflicts of interest” in the policy title. Five 
(13%)  policies  were  cross-referenced  to  other  relevant 
policies from their institution. Of the 2 teaching hospi-
tals that used internal and partner-university policies, 
neither cross-referenced the other’s policies. The ability 
of some leaders within an AHSC to identify a fCOI policy, 
while others based in the same AHSC could not, sug-
gested that communication within AHSCs about fCOI 
policies was limited. For example, one teaching hospital 
said that its submitted fCOI policy was also used by its 
parent  university;  however,  the  parent  university  re-
ported having no relevant policy. 
Table 1 describes a content analysis of the 38 unique 
policies. Definitions that informed our content analysis 
are listed in Box 2. Of the policies analyzed, 2 contained 
no items of relevance to institutional fCOI. On average, in-
dividual policies contained 20% of the 16 core “standard” 
items: no individual policy contained more than 65% of 
the core fCOI items. Even when the content of up to 3 poli-
cies per site was combined, less than half of the core items 
were addressed. Less than a quarter of policies addressed 
royalties, equity interest, or ownership interests. 
Our results demonstrate that more than half of Can-
adian  universities,  half  of  medical  schools,  and  more 
than a third of teaching hospitals had no institutional 
fCOI policy at the time of our survey. This is consistent 
with a 2006 survey of 86 deans of US medical schools 
(response rate 86/125), which found that fewer than half 
(38%) reported adopting an institutional fCOI policy.18 
Further, policies were inadequately comprehensive and 
often difficult to locate.
Like all studies, our work has limitations. First, we re-
quested a maximum of 3 policies from each site; some 
may speculate that this truncated our results if sites had 
more than 3 policies relating to the core fCOI items. (For 
example, the Pennsylvania School of Medicine reports 
having more than 90 policies regarding conflicts of in-
terest.19 However, given that 33 of 74 (45%) sites reported 
no relevant policies and only 10 (13%) sites identified 3, 
we think this is unlikely. 
Second, we used a stringent definition of “policy” and 
recognize  that  this  would  have  excluded  other  terms 
used to label policies (e.g., “protocols,” “statements” or 
“standards”).  Moreover,  a  strategic  position  taken  by 
the institution or mechanisms to deal with institutional 
fCOI could have been in place without being articulated 
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Box 1:  Description of methods
We de￿  ned a document as a policy if the word “policy” appeared 
in the title or was used to describe the document. To identify rel-
evant fCOI policies, 2 reviewers (JG and MS) identi￿  ed all poten-
tial fCOI policies that were publicly available from the websites 
of each university, its medical school, and all its fully a€   liated 
teaching hospitals. Next, we contacted the vice-president (VP) 
of research (or equivalent) at each site and asked him or her to 
identify 3 key institutional fCOI policies. The VPs could identify 
these from our list, or they could identify other policies they con-
sidered more relevant. Draft policies were accepted (no ￿  nalized 
policies were received). Non-responders were sent a maximum of 
8 email reminders. Finally, in 2006 we sent each VP of research a 
letter listing their 3 key policies. In addition, each institution was 
given aggregate policy content data so they could evaluate their 
performance relative to other institutions in the country. We in-
vited them to contact us with questions or concerns related to 
their information. 
To evaluate the policy comprehensiveness, we compared each 
unique policy to our “standard” of 16 core items relevant to insti-
tutional fCOI derived from 3 key COI documents2,10,11 (see Table 
1). Two reviewers independently reviewed each unique policy 
(31 English [MS and JG] and 7 French [MS and MEC]) to identify 
the core items. There was good agreement between the asses-
sors (Kappa statistics: 0.77 and 0.81, respectively). 
We identi￿  ed a subset of “institutional fCOI-speci￿  c policies” as 
those containing the phrase “institutional conš  icts of interest” in 
the title, a de￿  nition of institutional fCOI within the policy, or a 
statement indicating that the policy addressed institutional fCOI.
We assessed policy accessibility by evaluating the ability of an 
individual  to  access  the  policy.  First,  we  determined  whether 
institutional COI was in the policy title. Second, we determined 
whether  the  policies  were  cross-referenced  to  the  policies  of 
other a€   liated institutions. Open Medicine 2010;4(3):e136
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in a policy and thus would have been missed by our re-
search method. 
Third, our research focused on the adoption of policies 
and gave particular attention to their comprehensiveness. 
This does not capture the measures established at each 
institution to manage fCOI. Some AHSCs may have very 
detailed  policies  that  are  ineffective  because  they  are 
not implemented or enforced, while others may have a 
Table 1: Comprehensiveness of institutional fCOI policies* at Canadian academic health sciences centres† (universities, 
medical schools‡ and teaching hospitals)
Level Policy description
Any level University
Teaching 
hospital
Speci￿  c to 
institutional fCIO General
Institutional fCOI domains and items§
No. (%) 
(N = 13)
No. (%) 
(N = 25)
No. (%) 
(N = 9)
No. (%) 
(N = 29)
No. (%) 
(N = 38)
De￿  nitions 7 (54) 7 (28) 9 (100) 5 (17) 14 (37)
Policy title includes “institutional COI” 3 (23) 3 (12) 6 ( 67) 0 6 (16)
De￿  nition of institutional COI 2 (15) 2(8) 4 (44) 0 4 (11)
De￿  nition of ￿  nancial COI 5 (38) 3 (12) 3 (33) 5 (17) 8 (21)
Categories of institutional conŠ  icts covered 12 (92) 24 (96) 9 (100) 27 (93) 36 (95)
Institution 4 (31) 3 (12) 4 (44) 3 (10) 7 (18)
Senior institutional o€   cials¶ 12 (92) 23 (92) 9 (100) 26 (90) 35 (92)
Scope of ￿  nancial interests covered 8 (62) 14 (56) 5 (56) 17 (59) 22 (58)
Royalties from sale of the investigational product that is the 
subject of research
5 (38) 3 (12) 4 (44) 4 (14) 8 (21)
Equity interest or an entitlement to equity of any value in a 
non-publicly traded sponsor of human subjects research at the 
institution 
5( 38) 1 (4) 3 (33) 3 (10) 6 (16)
Ownership interest or an entitlement to equity in a publicly 
traded sponsor of human subjects research at the institution
5(38) 1 (4) 3  (33) 3 (10) 6 (16)
Institutional o€   cials with direct responsibility for human subjects 
research hold a signi￿  cant ￿  nancial interest in a commercial 
research sponsor or investigational product
8(62) 13 (52) 5 (56) 16 (55) 21 (55)
Management of potential institutional fCOI 6(46) 6 (24) 4 (44) 8 (28) 12 (32)
Reporting and review process
Institutional COI committee exists 2 (15) 2 (8) 1 (11) 3 (10) 4 (11)
Disclosure/reporting of institutional COI  required 3 (23) 4 (16) 3 (33) 4 (14) 7 (18)
Disclosure to the REB required 1 (8) 1 (4) 1 (11) 1 (3) 2 (5)
Rebuttable presumption against conduct of human subjects 
research when institutional level fCOI exists
1 (8) 0 0 1 (3) 1 (3)
Procedure for conducting institutional-level audits for COI 1 (8) 2 (8) 1 (11) 2 (7) 3 (8)
    Separation strategies
Technology transfer at the institution separate from the human 
subjects research administration
2 (15) 0 0 2 (7) 2 (5)
Endowment/investments managed externally through legally 
separate organizations
0 0 0 0 0
Overall
Number of core items covered 
(Total 16 core items)
Mean (SD)  4.5 (3.3)  2.4 (1.8)  5.2 (3.2) 2.5 (2.0) 3.2 (2.6) 
Mean percentage 28 15 32 16 20
Median (range) 3 (0–10) 2 (0–9) 4 (2–10) 2 (0–8) 2 (0–10)
   Abbreviations: COI = conš  icts of interest; fCOI = ￿  nancial conš  icts of interest; REB = research ethics board.
* One university policy and 2 teaching hospital policies were sent as drafts. 
† Canadian academic health sciences centres (AHSCs) are universities with medical schools that have a€   liated teaching hospitals. There were 16 AHSCs in
    Canada. A 17th Canadian academic health sciences centre was excluded because its medical school was newly established and it was in the policy develop
    ment stage.
‡ No medical school level policies.
§ The 16 core items relevant to institutional fCOI used in our survey were derived from 3 key COI documents (AAU Report 2001,10 AAMC Report 2002,2 and
   AAMC Survey 200411).  The most current report (AAMC Report 20081) also contained these core items and provided further clari￿  cation around     
    these issues.
¶ Senior institutional o€   cials were described as senior institution o€   cials, member of board of trustees, member of the board of governors, 
    president, vice presidents, deans, directors, or all sta°   in the policies.poorly  developed  formal  policy  while  still  having  ef-
fective  mechanisms  to  address  and  manage  institu-
tional fCOI. Even detailed policies may not be sufficient 
to anticipate all issues related to institutional fCOI that 
could arise within an academic institution.20 While sim-
ply having a comprehensive policy is not sufficient, it is 
a usual means of communicating expected standards in 
academic institutions.18
Fourth, the list of the 16 items we used to evaluate the 
comprehensiveness of a policy was based on information 
from the AAMC2,11 and the AAU  10 that was available at 
the time of our survey. The 2008 AAMC template policy1 
contains the 16 core items we identified as being central 
to an institutional fCOI policy and adds further clari-
fication. We expect that relevant policy items will con-
tinue to evolve. Further, we evaluated only whether the 
policy mentioned the core fCOI items. An evaluation of 
the quality of information provided about each core item 
may reveal further deficiencies. 
Finally, this study was conducted on policies in place 
in 2006. Given the requirement for Canadian institutions 
holding federal funds to put conflict-of-interest policies 
in place by January 2009,21 we expect that many Can-
adian AHSCs are actively developing and implementing 
their institutional fCOI policies. Attention will need to 
be paid to having university-wide fCOI policies that are 
sensitive  enough  to  capture  issues  specific  to  medical 
schools, or allowances will need to be made for medical 
schools to have a supplemental fCOI policy. 
In summary, over half of the Canadian AHSCs lacked 
institutional  fCOI  policies  at  the  time  of  our  survey. 
Where  policies  existed,  they  were  not  comprehensive 
and were frequently difficult to access. The 2008 Re-
port of the AAMC-AAU Advisory Committee on Finan-
cial Conflicts of Interest in Human Subjects Research1 
offers a thoughtful discussion on the complex institu-
tional fCOI issues and provides a useful template for in-
stitutional policy. Other hospitals and universities that 
are not affiliated with AHSCs will also need to develop 
fCOI policies if they receive Canadian Tri-Council fed-
eral funds. Professional societies and those involved in 
clinical practice guideline development may also wish to 
develop these policies.22 We trust that our results related 
to core policy items will support appropriate policy de-
velopment in this area.
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Box 2: Glossary of terms
Academic health science centres (AHSCs)
“Academic health science centre (AHSC) refers to [the] university, 
its  medical  school,  and  the  teaching  hospitals  who  agree  to 
[work collectively toward] a mission of excellence in education, 
research, and clinical care.”12
Conš  icts of interest 
“A set of conditions in which professional judgment concerning 
a primary interest (such as a patient’s welfare or the validity of 
research) tends to be unduly inš  uenced by a secondary interest
(such as ￿  nancial gain).”13
Endowment
“Gift of money or property to a speci￿  ed institution for a speci￿  ed 
purpose.”14
Equity interest
“Ownership interest in a company.”14
Institutional ￿  nancial conš  icts of interest
“An institution may have a conš  ict of interest in human subjects 
research whenever the ￿  nancial interests of the institution, or 
of an institutional o€   cial acting within his or her authority on 
behalf  of  the  institution,  might  a°  ect—or  reasonably  appear 
to  a°  ect—institutional  processes  for  the  conduct,  review,  or 
oversight of human subjects research.”2
Investigator conš  icts of interest
“A  situation  in  which  a  person  [such  as  a  public  o€   cial,  an 
employee, or a professional] has a private or personal interest 
su€   cient to appear to inš  uence the objective exercise of his or 
her o€   cial duties.”15
Publicly traded 
“A company that has held an initial public o°  ering and whose 
shares are traded on a stock exchange or in the over-the-counter 
market. Public companies are subject to periodic ￿  ling and other 
obligations under federal securities laws.”14
Rebuttable presumption
“The presumption that individual [investigators] may not conduct 
research [that is related to their own ￿  nancial interests].”16
Royalties
“Payment for the right to use intellectual property or natural 
resources.”14
Technology transfer
“The process by which basic science research and fundamental 
discoveries  are  developed  into  practical  and  commercially 
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